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Abstract
Objective: HIV ‘‘elite controllers’’ (ECs) spontaneously control viral load, but some eventually require combination
antiretroviral treatment (cART), due to a loss of viral control or a decline in CD4 T-cell counts. Here we studied the CD4 T-cell
count dynamics after cART initiation among 34 ECs followed in U.S. and European cohorts, by comparison with chronically
viremic patients (VIRs).
Methods: ECs were defined as patients with at least $5 viral load (VL) measurements below 400 copies/mL during at least a
5-year period despite never receiving ART and were selected from the French ANRS CO18 cohort, the U.S. SCOPE cohort, the
International HIV Controllers study and the European CASCADE collaboration. VIRs were selected from the ANRS COPANA
cohort of recently-diagnosed (,1 year) ART-naı ¨ve HIV-1-infected adults. CD4 T-cell count dynamics after cART initiation in
both groups were modelled with piecewise mixed linear models.
Results: After cART initiation, CD4 T-cell counts showed a biphasic rise in VIRs with: an initial rapid increase during the first 3
months (+0.63
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
/month), followed by +0.19
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
/month. This first rapid phase was not observed in ECs, in whom the
CD4Tc count increased steadily, at a rate similar to that of the second phase observed in VIRs. After cART initiation at a CD4
T-cell count of 300/mm
3, the estimated mean CD4 T-cell gain during the first 12 months was 139/mm
3 in VIRs and 80/mm
3
in ECs (p=0.048).
Conclusions: cART increases CD4 T-cell counts in elite controllers, albeit less markedly than in other patients.
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Introduction
Current guidelines in industrialized countries shift to recom-
mend antiretroviral treatment for all HIV-infected patients.
Combination antiretroviral therapy (cART), whether started
during the primary infection or in the chronic phase of HIV-1
infection, generally leads to a biphasic increase in CD4 T cell
counts, with a rapid increase during the first months, followed by a
more gradual rise [1–4]. At least 80% of patients are expected to
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85516achieve viral control after 6 months of treatment, with a median
CD4 T cell increase of about 100 CD4/mm
3 [5–7].
‘‘Elite Controllers’’ (ECs) are HIV-1-infected individuals in
whom viral replication is spontaneously controlled for several
years [8–12]. ECs represent about 1% of all HIV-1-infected
patients [13–15]. The time course of CD4 T cell counts is variable
in ECs and eventual loss of HIV control or marked CD4 T cell
depletion sometimes necessitates cART initiation. Chronic
immune activation and inflammation are another possible
indication for cART in these patients. Two previous studies have
examined the impact of cART in ECs. In the first, the CD4 T cell
increase in the six ECs studied tended to be smaller than in other
patients [16]. The second [17], more recent study, examined the
impact of cART on immune activation in 16 ECs: markers of T
cell activation and HIV RNA load decreased during 24 weeks of
cART, but no change in the CD4 T cell count was noted.
Additional information is therefore necessary to clarify the impact
of cART on the CD4+ T cell count in ECs.
Here, we studied the response to first-line cART among 34 ECs
participating in several HIV controller cohorts in the USA and
Europe. CD4 T cell count dynamics were compared to those
observed in chronically infected patients also starting first-line
cART at the chronic stage.
Methods
ECs were identified from the French ANRS CO18 HIV
Controllers cohort [18], the San Francisco Bay Area cohort
(SCOPE Cohort) [19], the International HIV Controllers Study
[20], and the CASCADE collaboration which includes HIV
seroconverters from 28 European, Canadian, Australian and sub-
Saharan African cohorts [21]. In order to harmonize the definition
of ECs across the cohorts, we adopted the ANRS definition [21],
i.e. patients with a minimum of 5 viral load (VL) measurements
below 400 copies/mL over a minimum of 5 years despite never
receiving ART. Interestingly, all the selected patients also fulfilled
the American elite controller definition, i.e. at least 3 VL
determinations below the assay detection limit (generally ,50
copies/mL) spanning greater than 12 months in the absence of
ART for $1 year before and during the period of virologic control
[12,22]. We studied ECs who received cART for whatever reason
(VL increase or CD4T cell loss), apart from transient prevention of
mother-to-child transmission, and who had at least two available
CD4 cell counts after cART initiation, in order to model the
dynamics of CD4 T cell counts.
VIRs were selected from the ANRS COPANA Cohort in which
recently diagnosed (,1 year) cART-naı ¨ve HIV-1-infected patients
have been enrolled since 2004. Among 800 enrolled individuals,
we studied the 478 patients who initiated cART and who had at
least two CD4 cell counts after cART initiation. All the
participants gave their written informed consent. Clinical inves-
tigations were conducted according to the principles of the
Declaration of Helsinki and all the cohorts were approved by local
ethics committees. Ethical approvals for each cohort are detailed
in the appendix.
Statistical Analysis
Baseline demographic and immuno-virological characteristics at
the time of cART initiation were described by the median and
interquartile range for continuous variables, and percentages for
discrete variables. CD4 T cell counts and HIV viral loads at cART
initiation were defined as the last available values before treatment
initiation. Univariate and multivariate (adjusted for sex and age at
cART initiation) mixed-effect linear models in ECs and VIRs
patients were used to estimate changes in CD4 cell counts from
cART initiation. These models were chosen in order to take into
account the fact that the subjects had repeated CD4 measure-
ments. The best models were chosen by applying likelihood ratio
tests or Akaike information criterion. Given the available number
of CD4 T cell counts, we chose to model CD4 T cells dynamics for
the first 15 months after cART initiation, during which the median
numbers of available CD4 measurements was 4 [IQR: 3–6].
Square root transformation of CD4 T cell counts was used to fulfill
the model assumptions. To facilitate understanding of the results,
estimates were also provided in absolute CD4 T cell numbers by
squaring intercept and increase given by the model. SAS (Version
9.3, 2003; SAS Institute Inc., Cary, NC, USA) and STATA
software (Version 12.0, 2009; Stata Corp., College Station, Texas)
were used for statistical analysis.
Results
Characteristics of ECs and VIRs
Main characteristics of ECs and VIRS are resumed in Table 1.
We did not observe any difference in gender between groups, but
men who have sex with men were less frequent among ECs than
among VIRs (32% vs. 62% respectively; p,0.001). More ECs
were IVDUs or infected through other haematogenous routes than
VIRs (41% vs 2%; p,0.001), although some data were missing for
this parameter. Patients of sub-Saharan African, Caribbean and
African-American origin were less frequent among ECs than
among VIRs (11.8% vs 40.6%; p,0.001). As expected, the year of
infection was less recent in ECs than in VIRs, consequently, the
time from HIV diagnosis to ART initiation was much longer in
ECs (median 16 years vs 1 year; p,0.001). Finally, ECs were
younger than VIRs at HIV diagnosis but older at cART initiation
(both p,0.001).
Fifty percent of ECs were HCV and HBV seronegative while
compared to only 29% of VIRs, while 15% of ECs were
seropositive for both HCV and HBV compared to only 3% of
VIRs. The proportion of HCV positive/HBV negative patents
was higher among ECs than among VIRs patients (15% vs 2%)
while the proportion of HCV negative/HBV positive was higher
in VIRs patients (3% vs 57%). This latter difference was consistent
with the higher frequency of sub-Saharan African, Caribbean and
African-American origin among VIRs and the higher rate of HCV
positivity among ECs was consistent with their higher frequency of
infection through IVDU or other haematogenous route of
infection. As expected, AIDS diagnosis before cART initiation
was very rare in ECs with only two cases (low-grade lymphoma
and Pulmonary Tuberculosis) vs 55 (12%) cases in VIRs patients
(27.3% Pneumocystosis Pneumonia (PCP) and 20.0% Pulmonary
Tuberculosis).
The initial cART regimen in ECs mainly consisted of
NRTI+NNRTI (44.1%, mostly 2 NRTI+1 NNRTI) followed by
NRTI+PI in 26.5% of cases; 14.7% of ECs received a
combination of NRTI+integrase inhibitors. In contrast, 64.2% of
VIRs received NRTI+PI and 28.7% received 2 NRTI+1 NNRTI.
The respective median CD4 cell counts in the ECs and VIRs,
before treatment initiation, were 268/mm
3 (range: 95–1249/mm
3)
and 255/mm
3 (range: 2–998/mm
3) (Wilcoxon rank sum test:
p=0.02) and the respective median viral loads were 2.0 log
copies/mL (range: 1.3–3.4 copies/mL) and 4.8 log copies/mL
(range: 1.6–6.5/copies/mL) (p,0.001).
cART initiation in ECs appears to have been prompted more
by a decline in CD4 T cells than by a loss of viral control. In ECs,
baseline viral load was measured a median of 38 days [IQR:273;
0 day] before cART initiation: viral load was ,50 copies/mL in
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from the ANRS COPANA Cohort.
Characteristics Elite Controllers COPANA Cohort Study p
Patient recruitment (TreatedECs/TotalECS*)
ANRS CO18 cohort 9/186
CASCADE collaboration 12/140
SCOPE cohort 7/100
The International HIV Controllers Study 6/450
Women (%) 9 (26.5) 149 (31.2) 0.57
Route of infection
Sexual 19 (55.9) 409 (85.6) ,0.001
IVDU 10 (29.4) 3 (0.6)
Other hematogenous routes (hemophiliacs or transfusions) 3 (8.8) 6 (1.3)
Unknown 2 (5.9) 60 (12.6)
Sexual preference among men n=25 n=329
Heterosexual 9 (36.0) 123 (37.4) ,0.001
Men who have sex with men 8 (32.0) 204 (62.0)
Unknown 8 (32.0) 2 (0.6)
Ethnicity
White 19 (55.9) 270 (57.1) ,0.001
BSSA/Car/BA** 4 (11.8) 192 (40.6)
Other 3 (8.8) 11 (2.3)
Unknown 8 (23.5) –
Year of HIV diagnosis 1992 [1986–1999] 2005 [2004–2006] ,0.001
Age at HIV diagnosis 29 [25–33] 35 [29–44] ,0.001
HCV and HBV serostatus
Both positive 5 (15.0) 14 (3.0)
HCV
+ and HBV
2 5 (15.0) 8 (2.0)
HCV
2 and HBV
+ 1 (3.0) 271 (57.0)
Both negative 17 (50.0) 141 (29.0)
At least one of the two 5 (15.0) 33 (7.0)
Unknown 1 (3.0) 11 (2.0)
AIDS diagnosis before cART initiation 2 (6.0) 55 (12.0) 0.41
Year of cART initiation 2008 [20006–2010] 2007 [2005–2008 ) 0.002
Age at cART initiation 45 [38–51] 37 [30–45] 0.0001
Time frome HIV-1 diagnosis to cART initiation (years) 16 [9–20] 1 [0–1] ,0.001
Initial cART regimen
NRTI alone 2 (5.9) 17 (3.6)
NRTI+Integrase Inhibitors 5 (14.7) –
NRTI+PI 9 (26.5) 307 (64.2)
NRTI+NNRTI 15 (44.1) 137 (28.7)
Others 3 (8.8) 17 (3.5)
Median CD4/mm
3 at cART initiation 268 [212–445] 255 [161–327]
Mean CD4/mm
3 at cART initiation (range) 348 (95–1249) 257 (2–998) 0.02
Median viral load log10 copies/mL at cART initiation 2.0 [1.7–2.6] 4.8 [4.2–5.3]
Mean viral load log10 copies/mL at cART initiation (range) 2.2 (1.3–3.4) 4.7 (1.6–6.5) ,0.001
Data are median [IQR] or n (%);
*According to own cohort’s definitions of ECs;
**SSA/Car/BA=Sub-Saharan African, Caribbean or African-American origin.
doi:10.1371/journal.pone.0085516.t001
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copies/mL in 18%. The median CD4 cell count in ECs was low
with a wide range of individual values (95 to 1249/mm
3).
CD4 Cell Count Kinetics in ECs after cART Initiation
In ECs the first on-treatment CD4 cell T count was measured
after a median of 27.4 days [3.0–42.6 days]. Several piecewise
models were tested. The best fit was obtained with a model having
only one slope of CD4 T cells. The mean intercept was estimated
to be 17.79
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
[16.04–19.53]. The mean CD4 T cell increase
was estimated to be +0.19
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
[+0.06-+0.32] per month until
month 15, a value significantly different from zero (p=0.006). For
example, an EC who started cART at 316 CD4/mm
3 (i.e. squared
intercept) would reach counts of 337, 358 and 402 CD4/mm
3,
respectively, 3, 6 and 12 months after cART initiation. Introduc-
tion of sex and age at cART initiation in the model had no marked
impact on these results. The CD4 cell count at cART initiation,
categorized as ,350 (n=20) and $350 CD4/mm
3 (n=14) did
not influence the CD4 cell slope, and neither did VL categorized
as ,50 vs $50 copies/mL. To note, the slope of the CD4 T cells
in the 6 patients who initiated cART with a viral load .1000
copies/mL was not much steeper (+0.17
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
per month) than
the mean slope estimated in other ECs. Despite the small sample
of HCV
neg patients (n=11), the estimated slope of the CD4 T cells
showed, as in other ECs, a monophasic phase of increase after
cART initiation.
Differences in On-treatment CD4 T Cell Kinetics between
ECs and VIRs
We then compared these CD4 T cell kinetics with those
observed in VIRs from the ANRS COPANA cohort. Among
VIRs, the median CD4 cell count at cART initiation was 255/
mm
3 [range: 2–998] and median viral load was 4.7 log copies/mL
[range: 1.6–6.5]. The on-treatment CD4 T-cell count was
measured a median of 27 days after cART initiation and the
median number of CD4 T-cell counts obtained during the first 15
months of treatment was 5 [IQR:4–7]. Several piecewise models
(one or more slopes, nodes at different times after cART initiation)
were tested for VIRs. The best fit was obtained with a two-slope
model with a node at 3 months following cART initiation, in
agreement with previous reports [1–4]. According to this model,
the mean intercept was estimated at 17.03
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
[16.52–17.55]. A
marked initial increase of +0.63
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
[+0.50–+0.77] per month
was observed during the first 3 months, followed by a significant
but more gradual increase of +0.19
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
[20.092+0.48] per
month (both ,0.001). For example, a VIR starting cART at 290
CD4/mm
3 (i.e. squared intercept) would reach 358 CD4/mm
3 at
month 3 (average +23 CD4 cells/month) and 427 CD4/mm
3
(average +8 CD4 cells/month from month 4).
Figure 1 describes CD4 T cell dynamics during the first 15
months of cART in each group. By including data from the two
groups in the same model, we were able to compare the CD4 gain.
Twelve months after treatment initiation, the mean CD4 T cell
gain was significantly larger in the VIRs than in ECs (p=0.048)
whatever the baseline count. Adjustment for sex and age at cART
initiation did not affect these results. For an EC and a VIR
beginning cART at a similar CD4 cell count of 300/mm
3, the
respective mean gain at 12 months would be 80/mm
3 and 139/
mm
3.
The median year of cART initiation was 2008 in both groups,
but the initial cART regimens differed significantly between ECs
and VIRs (p,0.001): an NNRTI-based combination was more
frequently prescribed to ECs than VIRs, while a PI-based
combination was more often prescribed to VIRs than ECs. Only
ECs received NRTI+integrase inhibitor (raltegravir
) combina-
tion. The number of ECs was too small to examine the influence of
the different cART regimens. However, NNRTI-based cART was
associated with a two-phase CD4 T-cell increment in VIRs,
indicating that the absence of the first slope in ECs was unlikely to
be due to a different choice of cART regimens.
In summary, the CD4 T-cell increment in chronically viremic
patients starting first-line cART was biphasic with an initial rapid
increase during the first 3 months followed by a more gradual
increase of +0.19
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CD4
p
per month. ECs experienced no such
initial rapid increment and their monophasic CD4 T-cell slope
was very similar to the second slope observed in VIRs. As a result,
the mean CD4 T-cell gain 12 months after cART initiation was
significantly smaller in ECs than in VIRs.
Discussion
The main result of this study is that cART increases the CD4 T-
cell count in elite controllers, albeit relatively slowly, even in ECs
who had experienced a large decline in their CD4 T cell count
during the period of spontaneous control (50% of the ECs had
counts below 268/mm
3 at cART initiation). Two previous studies
have studied the response to cART in ECs. The first was too small
to draw firm conclusions [16], while the second showed no
significant increase in the CD4 T cell count [17]. However,
patients in the latter study had a higher median CD4 T cell count
(616/mm
3) than those in our study (268/mm
3). Moreover, the
patients in our study were treated for much longer than those
described by Hatano et al. (15 vs 6 months).
Results from our study strongly suggest that the low levels of
viral replication detectable with ultra-sensitive plasma HIV RNA
assays in nearly all ECs [23] contribute to immunological attrition.
Interestingly, viral escape seems to be both a rare event and a rare
indication for cART in ECs, as only 6 patients in our study started
cART at VL.1000 copies/mL. Another major finding of our
study is that CD4 T-cell recovery is far less rapid and marked in
ECs than in chronically viremic patients also starting a first-line
cART. There are several possible explanations for this difference.
First, high viral load at cART initiation, in chronically viremic
patients, is associated with a steep initial increase in CD4 T-cell
numbers, whereas the ECs in our study had undetectable or low
viral load values at treatment initiation [6,7,16]. Second, although
the seroconversion dates were not known for most of the study-
patients, time since diagnosis was significantly longer in ECs than
in VIRs. It is possible that durable T-cell-mediated control of
infection, which would require continuous renewal of effective
HIV-specific CD4 and CD8 T cells, may cause an exhaustion of
hematopoietic progenitor cells in some ECs. Along these lines,
severe CD4 T cell loss in ECs has been linked with impaired
lymphopoiesis [24] and reduced thymic output [25]. Third,
hepatitis C virus co-infection was more frequent in ECs than in
VIRs in our study (32.3% vs 5.0%) [26]. HCV co-infection has
been associated with a lower recovery of CD4 T cell counts during
antiretroviral therapy [27–28], but conflicting results exist on this
regard [29]. Limited redistribution of CD4 T cells from lymphoid
tissues might also explain the lack of an initial, rapid CD4 cell
increment in ECs, as this is the main mechanism underlying the
first phase of CD4 T cells recovery in VIRs starting cART [30].
Finally, high levels of systemic inflammation correlate with low
CD4 T cells counts in ECs [31] and are attenuated by cART [17].
This relatively slow CD4 cells recovery implies that it would
take much longer for an elite controller to reach a target count of
around 500/mm
3. From a clinical point of view, early cART
Blunted Response to cART in HIV Controllers
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their CD4 T cell count in order to avoid lengthy periods with
persistently low CD4 T cell counts during treatment. It is
important to keep or recover an adequate CD4 T cell count as
AIDS-related morbidity in HIV-infected patients increase signif-
icantly at counts below 750/mm
3 [32].
One limitation of this study is that follow-up on cART (15
months) was too short to determine long term immunological
outcome. Moreover, the study population was too small to explore
whether particular antiretroviral combinations may be more
effective than others in ECs. CD4 T-cell percentages were also
unavailable for most of our patients and we could not therefore
compare patients with a decrease in both the CD4 T-cell count
and percentage with those who became lymphopenic but had a
stable percentage of CD4 T cells. Finally, it remains to be seen
whether elite controllers are still able to control viral replication
spontaneously after cART interruption and CD4 T cell recovery
[33], but personal unpublished observational data from pregnant
women in our cohorts suggest that this could be the case.
This study provides important information for clinicians caring
for HIV elite controllers. Loss of CD4 T cells below 750/mm
3 is
associated with AIDS-defining events in other patients [32]. The
best ART combination for these patients remains to be defined.
An interesting therapeutic option could be an addition of immuno-
modulatory drugs to cART in elite controller.
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